Business Context and Reporting Period
Company: Dermata Therapeutics, Inc. (DRMA)
Filing Type: Form 8-K (Current Report)
Date of Report: December 23, 2025
Event: Entry into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Net Proceeds: Approximately $3.7 million (after placement agent fees and estimated offering expenses).
- Securities Issued:
- 1,484,312 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 537,750 shares (Exercise Price: $0.001).
- Series C Warrants to purchase up to 2,022,062 shares (Exercise Price: $2.04; Expiration: 5 years post-approval).
- Series D Warrants to purchase up to 2,022,062 shares (Exercise Price: $2.04; Expiration: 24 months post-approval).
- Purchase Price: $2.04 per Share (with accompanying Warrants) and $2.039 per Pre-Funded Warrant (with accompanying Warrant).
- Insider Participation: Company insiders (including CEO and CFO) purchased an aggregate of 735,294 Shares and Warrants for approximately $1.5 million.
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a cash fee of 7.0% on outside investor proceeds, 3.5% on insider proceeds, a 1.0% management fee, and warrants to purchase 141,544 shares at $2.55 per share.
Material Changes and Agreements
- Warrant Amendments: The Company amended outstanding warrants (originally issued Jan 23, 2025, with a $12.70 exercise price) to reduce the exercise price to $2.04 per share for participating investors.
- Registration Rights: The Company agreed to file a registration statement within 30 days and have it declared effective within 60 days (or 90 days if a full SEC review occurs).
- Lock-Up Provisions: The Company agreed not to issue additional Common Stock or equivalents for 30 days after the registration statement becomes effective and is restricted from Variable Rate Transactions for one year.
- Beneficial Ownership Limits: Holders are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% with notice).
Use of Proceeds and Outlook
The Company intends to use the net proceeds for general corporate purposes, specifically:
- Consumer research studies.
- Pre-launch and launch activities for a new OTC acne kit.
- Investing in or acquiring synergistic companies or emerging technologies.
- Licensing activities related to current and future product candidates.
- Working capital.
Management Commentary: The filing does not provide specific forward-looking financial guidance or revenue projections beyond the stated use of proceeds.
Investor Verification Checklist
- Verify the effective date of the registration statement to determine when Warrants become exercisable.
- Confirm the dilution impact of the 1,484,312 new shares and the potential issuance of up to 4,044,124 shares via Warrants.
- Review the specific terms of the "Black Scholes Value" payout provision in the event of fundamental transactions.
- Monitor the timeline for the filing and effectiveness of the registration statement (30/60/90-day deadlines).
- Assess the financial runway provided by the $3.7 million net proceeds relative to the stated development and launch costs.